Myriad Genetics Inc (MYGN)

Apr 01, 2025

10 Analysts Assess Myriad Genetics: What You Need To Know - Benzinga

Apr 01, 2025

Apr 01, 2025

(MYGN) Technical Data - news.stocktradersdaily.com

Apr 01, 2025

Apr 01, 2025

Scotiabank cuts Myriad Genetics target to $20, keeps outperform rating By Investing.com - Investing.com Canada

Apr 01, 2025

Mar 31, 2025

Cancer Biomarkers Market Set to Witness Significant Growth - openPR.com

Mar 31, 2025

Mar 28, 2025

Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? - MSN

Mar 28, 2025

Mar 26, 2025

Myriad Genetics stock hits 52-week low at $9.36 amid challenges By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Myriad Genetics stock hits 52-week low at $9.36 amid challenges - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 26, 2025

Mar 25, 2025

Press Release Service: United States Molecular Diagnostics Market Forecast Report and Company Analysis 2025-2033 Featuring F Hoffmann-la Roche, Illumina, Hologic, Agilent, Qiagen, Myriad Genetics, Abbott, Danaher, BD & CoResearchAndMarkets.co - CRISPR Medicine News

Mar 25, 2025

Mar 22, 2025

Trend Tracker for (MYGN) - Stock Traders Daily

Mar 22, 2025

Mar 20, 2025

Global Preventive Healthcare Technologies And Services Market - openPR

Mar 20, 2025

Mar 17, 2025

The Future of Genetic Testing: Industry Growth, Trends & Key - openPR

Mar 17, 2025

Mar 17, 2025

Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance

Mar 17, 2025

Mar 16, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Not Doing Enough For Some Investors As Its Shares Slump 31% - Simply Wall St

Mar 16, 2025

Mar 15, 2025

Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup - MSN

Mar 15, 2025

Mar 12, 2025

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade - Benzinga

Mar 12, 2025

Mar 12, 2025

Myriad Genetics (MYGN) Stock Jumps on Analyst Upgrade - GuruFocus.com

Mar 12, 2025

Mar 12, 2025

Myriad Genetics Shares Rise After Upgrade From Piper Sandler -March 12, 2025 at 02:53 pm EDT - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Myriad Genetics stock upgraded at Piper Sandler (MYGN:NASDAQ) - Seeking Alpha

Mar 12, 2025

Mar 12, 2025

Why Are Myriad Genetics (MYGN) Shares Soaring Today - Yahoo Finance

Mar 12, 2025

Mar 12, 2025

This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga

Mar 12, 2025

Mar 12, 2025

Medical Equipment Stock Jumps on Upgrade - Schaeffers Research

Mar 12, 2025

Mar 12, 2025

Buy Rating on Myriad Genetics: Strategic Changes and Growth Potential Amid Challenges - TipRanks

Mar 12, 2025

Mar 12, 2025

Piper Sandler upgrades Myriad to 'overweight' on CEO change - TradingView

Mar 12, 2025

Mar 12, 2025

Piper Sandler Upgrades Myriad Genetics to Overweight From Neutral, Adjusts Price Target to $12.50 From $11.50 - Marketscreener.com

Mar 12, 2025

Mar 12, 2025

Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler - TipRanks

Mar 12, 2025

Mar 12, 2025

Morgan Stanley cuts Myriad Genetics stock target to $16 from $21 - Investing.com Canada

Mar 12, 2025

Mar 11, 2025

(MYGN) On The My Stocks Page - Stock Traders Daily

Mar 11, 2025

Mar 11, 2025

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks - Yahoo Finance

Mar 11, 2025

Mar 10, 2025

Myriad Genetics at Leerink Global Healthcare Conference: Strategic Growth Amid Challenges - Investing.com Canada

Mar 10, 2025

Mar 10, 2025

Myriad Genetics stock hits 52-week low at $9.74 amid challenges - Investing.com Canada

Mar 10, 2025

Mar 10, 2025

Myriad Genetics stock hits 52-week low at $9.74 amid challenges By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 07, 2025

Myriad Genetics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 07, 2025

Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Mar 07, 2025

Mar 06, 2025

Cancer Biomarkers Research Report 2024: Global Market Projected to Soar to USD 62.14 Billion by 2034, Driven by Technological Advancements and Increasing Demand for Early Detection - GlobeNewswire Inc.

Mar 06, 2025

Mar 06, 2025

Piper Sandler Lowers Myriad Genetics (NASDAQ:MYGN) Price Target to $11.50 - Defense World

Mar 06, 2025

Mar 05, 2025

US$19.13: That's What Analysts Think Myriad Genetics, Inc. (NASDAQ:MYGN) Is Worth After Its Latest Results - Yahoo Finance

Mar 05, 2025

Mar 03, 2025

Analyst Expectations For Myriad Genetics's FutureMyriad Genetics (NASDAQ:MYGN) - Benzinga

Mar 03, 2025

Mar 02, 2025

Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes - TipRanks

Mar 02, 2025

Mar 01, 2025

Myriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results - MarketBeat

Mar 01, 2025

Mar 01, 2025

Myriad Genetics (NASDAQ:MYGN) Lowered to Hold Rating by StockNews.com - MarketBeat

Mar 01, 2025

Mar 01, 2025

Myriad Genetics (NASDAQ:MYGN) Sets New 12-Month Low on Disappointing Earnings - MarketBeat

Mar 01, 2025

Feb 28, 2025

Myriad Genetics (NASDAQ:MYGN) Earns "Outperform" Rating from Raymond James - MarketBeat

Feb 28, 2025

Feb 28, 2025

UBS Group Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat

Feb 28, 2025

Feb 28, 2025

Leerink Partnrs Forecasts Myriad Genetics Q2 Earnings - MarketBeat

Feb 28, 2025

Feb 27, 2025

Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - GlobeNewswire

Feb 27, 2025

Feb 27, 2025

Myriad Genetics Partners With Gabbi To Offer Breast Cancer Risk Assessment & Care Solution - Nasdaq

Feb 27, 2025

Feb 27, 2025

Myriad Genetics Collaborates with Gabbi to Enhance Breast Cancer Risk Assessment and Care Services - Nasdaq

Feb 27, 2025